author-photo

Hui Huang

ARIAD Pharmaceuticals, Inc.
Takeda Pharmaceutical Company

44

Papers

227

Citations

Citation Trend

Filter By

Papers (36) Sort By

Journal Conference Others

Humanistic burden of living with anaplastic lymphoma kinase-positive non-small-cell lung cancer: findings from the ALKConnect patient insight network and research platform

2021 Lung cancer management
Show All
- Source
- Cite
- Save
Citations (0)
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.

2021 Annals of Hematology
Show All
- Source
- Cite
- Save
Citations (0)
Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors.

2020 Journal of Medical Economics
Show All
- Source
- Cite
- Save
Citations (1)
Patient-reported outcomes and quality of life in advanced ALK+ non-small-cell lung cancer trial of brigatinib (ALTA)

2019 Future Oncology
Show All
- Source
- Cite
- Save
Citations (5)
Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark RCTs in Relapsed/Refractory Multiple Myeloma

2019 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (30)
Efficacy of Ponatinib versus Earlier-Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia

2018 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (24)
Randomized Clinical Trial (RCT) Representativeness and Outcomes Among Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated in the Real World (RW): Comparison of ASPIRE, TOURMALINE MM1, POLLUX, AND ELOQUENT-2 RCTS

2018 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (3)
P1.15-16 ALKConnect: An Anaplastic Lymphoma Kinase Positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Patient Insights Network

2018 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
105PPrognostic factors in crizotinib (CRZ)-resistant anaplastic lymphoma kinase (ALK+) non-small cell lung cancer (NSCLC) patients (Pts)

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Survival Outcomes in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Receiving Third- or Subsequent Line (3L) Treatment

2017 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)